Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®

 Updated Functionality Seamlessly Integrates Mechanistic Modeling in Drug Discovery

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new collaboration agreement with a large pharmaceutical company to advance its ADMET Predictor® machine learning software for use within integrated drug discovery workflows. With the drugmaker’s input, Simulations Plus will develop enhanced capabilities in its existing HTPK Simulation Module which will incorporate physiologically based pharmacokinetic (PBPK) modeling into the partner’s discovery platform to support compound screening activities.

"We are pleased to announce this new collaboration which builds on a long-standing relationship with this partner. This effort will result in extended capabilities in high-throughput PBPK calculations at the discovery/development interface," said David Miller, director of ADMET Cheminformatics at Simulations Plus. "We are showing that it is now possible to front-load PK considerations at the discovery stage at an unprecedented level of speed and with more sophisticated models than ever before. The anticipated outcome from this collaboration is that such models will lead to improved efficiencies with less attrition in the transition from discovery into early development."

John DiBella, Lancaster division president for Simulations Plus, added: "We are grateful for the ability to obtain direct input from large pharma experts towards key enhancements to our technology platform. The machine learning-PBPK ‘marriage’ has been a strategic focus for us, and we are pleased to see more companies leveraging our best-in-class models and streamlined software engineering to complement their legacy screening methods. As with similar collaborations, Simulations Plus maintains the right to license the new functionality to all clients starting this year, and we continue to invite future collaborations to drive advances to modeling and simulation science which benefit our entire user community and, most importantly, patients that we serve."

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. Our software is used to conduct drug research by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading provider for physiologically based pharmacokinetic modeling and simulation. Visit us online www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like "believe," "expect" and "anticipate" mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005006/en/

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brett Maas
646-536-7331
slp@haydenir.com